Global Ophthalmics Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Ophthalmics Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the ophthalmics partnering deals and agreements entered into by the worlds leading healthcare companies

Global Ophthalmics Partnering 2010 to 2017 provides the full collection of Ophthalmics disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Ophthalmics partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Ophthalmics partnering agreement structure

Ophthalmics partnering contract documents

Top Ophthalmics deals by value

Most active Ophthalmics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Ophthalmics dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Ophthalmics deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Ophthalmics deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Ophthalmics partnering deals by specific Ophthalmics target announced since 2010. The chapter is organized by specific Ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Ophthalmics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Ophthalmics technologies and products.

Report scope

Global Ophthalmics Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Ophthalmics trends and structure of deals entered into by leading companies worldwide.

Global Ophthalmics Partnering 2010 to 2017 includes:

Trends in Ophthalmics dealmaking in the biopharma industry since 2010

Analysis of Ophthalmics deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Ophthalmics deal contract documents

Comprehensive access to over 3500 Ophthalmics deal records

The leading Ophthalmics deals by value since 2010

Most active Ophthalmics dealmakers since 2010

The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.

In Global Ophthalmics Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Ophthalmics Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Ophthalmics Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Ophthalmics deal trends since 2010

Access Ophthalmics deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Ophthalmics partner companies

Comprehensive access to over 750 links to actual Ophthalmics deals entered into by the world's biopharma companies

Indepth review of Ophthalmics deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Ophthalmics opportunities

Uncover companies actively partnering Ophthalmics opportunities

Global Ophthalmics Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ophthalmics dealmaking
2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Ophthalmics partnering
3.1. Introduction
3.2. Disclosed financials terms for Ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates

Chapter 4 - Leading Ophthalmics deals and dealmakers
4.1. Introduction
4.2. Most active in Ophthalmics partnering
4.3. List of most active dealmakers in Ophthalmics
4.4. Top Ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory
5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Ophthalmics therapeutic target

Appendices

Appendix 1 - Directory of Ophthalmics deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Ophthalmics deals by deal type 2010 to 2017
Appendix 3 - Directory of Ophthalmics deals by stage of development 2010 to 2017
Appendix 4 - Directory of Ophthalmics deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Ophthalmics partnering since 2010
Figure 2: Ophthalmics partnering by deal type since 2010
Figure 3: Ophthalmics partnering by industry sector since 2010
Figure 4: Ophthalmics partnering by stage of development since 2010
Figure 5: Ophthalmics partnering by technology type since 2010
Figure 6: Ophthalmics partnering by indication since 2010
Figure 7: Ophthalmics deals with a headline value
Figure 8: Ophthalmics deals with upfront payment values
Figure 9: Ophthalmics deals with milestone payment
Figure 10: Ophthalmics deals with royalty rates
Figure 11: Active Ophthalmics dealmaking activity- 2010 to 2017
Figure 12: Top Ophthalmics deals by value since 2010
  • United States Eye Drops & Lubricants Market Report 2017
    Published: 24-Jul-2017        Price: US 3800 Onwards        Pages: 96
    In this report, the United States Eye Drops & Lubricants market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth r......
  • United States Artificial Tears Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 19-Jul-2017        Price: US 4480 Onwards        Pages: 124
    This report studies the Artificial Tears market, Artificial tears are lubricant eye drops used to treat the dryness and irritation associated with deficient tear production in keratoconjunctivitis sicca (dry eyes). They are also used to moisten contact lenses and in eye examinations.Scope of the Report:This report focuses on the Artificial Tears in United States market, to split the market based on manufacturers, states, type and application.Market Segment by Ma......
  • Botulism - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 45
    Botulism - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H2 2017, provides an overview of the Botulism (Infectious Disease) pipeline landscape. Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the......
  • Global Eye Drops & Lubricants Sales Market Report 2017
    Published: 18-Jul-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Eye Drops & Lubricants market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Eye Drops & Lubricants for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe......
  • Ophthalmology Drugs Market Global Report 2017 Including: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy) Covering: Novartis AG, Regeneron, Allergan, F. Hoffmann-La Roche Ltd, and Pfizer Inc.
    Published: 17-Jul-2017        Price: US 4000 Onwards        Pages: 125
    Development of combination therapies for the treatment of eye related diseases including glaucoma is an emerging trend in the market. For instance, in September 2013, Alcon (a subsidiary of Novartis) received FDA approval for commercialization of its Simbrinza, a fixed dose combination drug without beta blocker used for the treatment of glaucoma. The Ophthalmology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they ne......
  • Global Eye Drops Market Professional Survey Report 2017
    Published: 10-Jul-2017        Price: US 3500 Onwards        Pages: 119
    This report studies Eye Drops in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Visine - Alcon - Viva - Opti-Free - Bausch & Lomb - Systane......
  • Asia-Pacific Eye Drops & Lubricants Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 07-Jul-2017        Price: US 4480 Onwards        Pages: 121
    Eye drops are saline-containing drops used as an ocular route to administer. Depending on the condition being treated, they may contain steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetics, parasympatholytics, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungal, or topical anesthetics. Eye drops sometimes do not have medications in them and are only lubricating and tear-replacing solutions.Scope of the Report:......
  • Diabetic retinopathy - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Diabetic retinopathy - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Diabetic retinopathy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Diabetic retinopathy prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associat......
  • Allergic Conjunctivitis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Allergic Conjunctivitis - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Allergic Conjunctivitis for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Allergic Conjunctivitis forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs